Genovis AB (publ) to publish Q3 2015 report ahead of schedule

The Board of Directors of Genovis AB (publ) has decided to publish Q3 2015 report ahead of schedule. 

The Interim Report for January-September, which was to be announced on November 23, 2015, will be published ahead of schedule. The new publication date for the report is November 3, 2015.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs. 

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). 

Genovis shares are listed on Nasdaq Stockholm First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.